Amplification of the int-2 gene in human head and neck squamous cell carcinomas.
Amplification of the int-2 gene in human head and neck squamous cell carcinomas.
复制标题
人头颈鳞状细胞癌中 int-2 基因的扩增。
作者：
Kenneth D. Somers;Cartwright Sl;Schechter Gl
应用Southern blot杂交技术对21例头颈部鳞状细胞癌（SCC）进行结构重排或扩增的原癌基因分析。10例喉部鳞状细胞癌中5例（50%）的int-2原癌基因扩增3-5倍，11例头颈部非喉部鳞状细胞癌中5例（45%）的int-2原癌基因扩增2-3倍。来自同一患者的相邻组织学正常组织具有单个int-2基因拷贝数。在1例喉部鳞状细胞癌和1例转移至颈部的鳞状细胞癌中发现了int-2和表皮生长因子受体（c-erbB-1）基因的共扩增。在所有头颈部肿瘤中未检测到原癌基因c-erbB-2/HER2、c-myc、H-ras-1或K-ras-2的扩增或结构改变。在一项头颈部肿瘤来源细胞系的调查中，int-2在一个下咽肿瘤细胞系（FaDu）中扩增9倍，但在3个喉部肿瘤细胞系中未扩增。Int-2定位于11号染色体的q13带。我们使用11号染色体特异性探针来证明int-2扩增不是由于11号染色体完全或部分重复。Int-2扩增定位于11q13位点，但未延伸至ets-1位点11q23。结果表明，int-2在头颈部鳞状细胞癌中经常扩增，并提示int-2扩增可能与临床疾病进展有关。
Head and neck squamous cell carcinomas (SCC) from 21 patients were analyzed for structurally rearranged or amplified proto-oncogenes by Southern blot hybridization. The int-2 proto-oncogene was amplified 3-5 fold in 5 (50%) of 10 laryngeal SCC and 2-3 fold in 5 (45%) of 11 nonlaryngeal SCC of the head and neck. Adjacent histologically normal tissue from the same patients had single int-2 gene copy number. Coamplification of int-2 and the epidermal growth factor receptor (c-erbB-1) gene was found in one laryngeal SCC and one SCC metastatic to the neck. No amplification or structural alterations of proto-oncogenes c-erbB-2/HER2, c-myc, H-ras-1, or K-ras-2 was detected in any of the head and neck tumors. In a survey of head and neck tumor-derived cell lines, int-2 was amplified 9 fold in a hypopharyngeal tumor cell line (FaDu), but not amplified in 3 laryngeal tumor cell lines. int-2 has been localized to the q13 band of chromosome 11. We used chromosome 11 specific probes to demonstrate that int-2 amplification was not due to complete or partial chromosome 11 duplication. int-2 amplification was localized to 11q13, but did not extend to the ets-1 locus 11q23. The results indicate that int-2 is frequently amplified in SCC of the head and neck and suggest that int-2 amplification may correlate with clinical disease progression.